BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Price, Quote, News and Overview
FRA:BIO3 - Deutsche Boerse Ag - DE0005227235 - Currency: EUR
BIO3.DE Quote, Performance and Key Statistics
FRA:BIO3 (5/23/2025, 1:53:46 PM)
30
0 (0%)
The current stock price of BIO3.DE is 30 EUR. In the past month the price increased by 15.38%. In the past year, price decreased by -23.66%.
BIO3.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.42 | 288.63B | ||
| AMG.DE | AMGEN INC | 14.21 | 137.04B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.03 | 116.61B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 102.50B | ||
| ARGX.BR | ARGENX SE | 106.49 | 30.04B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.69B | ||
| IDP.DE | BIOGEN INC | 7.94 | 15.90B | ||
| 0QF.DE | MODERNA INC | N/A | 10.56B | ||
| 1MRNA.MI | MODERNA INC | N/A | 10.54B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 1SRPT.MI | SAREPTA THERAPEUTICS INC | N/A | 1.64B | ||
| YTSN.DE | KUROS BIOSCIENCES AG-REG | N/A | 1.18B |
Related stock screener links
About BIO3.DE
Company Profile
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Company Info
BIOTEST AG-VORZUGSAKTIEN
Landsteinerstr. 5
Dreieich HESSEN DE
Employees: 2495
Phone: 4961038010
BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ
What is the stock price of BIOTEST AG-VORZUGSAKTIEN today?
The current stock price of BIO3.DE is 30 EUR.
What is the ticker symbol for BIOTEST AG-VORZUGSAKTIEN stock?
The exchange symbol of BIOTEST AG-VORZUGSAKTIEN is BIO3 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is BIO3.DE stock listed?
BIO3.DE stock is listed on the Deutsche Boerse Ag exchange.
What is BIOTEST AG-VORZUGSAKTIEN worth?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a market capitalization of 1.19B EUR. This makes BIO3.DE a Small Cap stock.
How many employees does BIOTEST AG-VORZUGSAKTIEN have?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) currently has 2495 employees.
What are the support and resistance levels for BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a support level at 28.48 and a resistance level at 30.01. Check the full technical report for a detailed analysis of BIO3.DE support and resistance levels.
Is BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) expected to grow?
The Revenue of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is expected to grow by 11.95% in the next year. Check the estimates tab for more information on the BIO3.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIO3.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIO3.DE, evaluating the profitability, health, valuation and growth aspects
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Sales and EPS estimates to see what analysts future expectations are.
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Chart to make your own analysis
- BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Latest news and press-releases to stay up to date.
Does BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock pay dividends?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a dividend yield of 0.09%. The yearly dividend amount is currently 0.04. Check the full fundamental report for a detailed analysis of BIO3.DE dividend history, reliability and sustainability.
When does BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) report earnings?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE)?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
BIO3.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BIO3.DE. When comparing the yearly performance of all stocks, BIO3.DE is a bad performer in the overall market: 87.75% of all stocks are doing better.
BIO3.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE. Both the profitability and the financial health of BIO3.DE get a neutral evaluation. Nothing too spectacular is happening here.
BIO3.DE Financial Highlights
Over the last trailing twelve months BIO3.DE reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -117.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| Debt/Equity | 1.26 |
BIO3.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to BIO3.DE. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 1600% and a revenue growth 11.95% for BIO3.DE